Description

Triplixam (perindopril arginine, indapamide, amlodipine) Coated Tablets 5 mg/1.25 mg/5 mg. №30 Vial

Ingredients

Active ingredients: Perindopril arginine, indapamide, amlodipine.

Dosage

Recommended dosage: One tablet daily, or as directed by a healthcare professional.

Indications

Indicated for: Treatment of hypertension in patients not adequately controlled with monotherapy.

Contraindications

Contraindicated in: Patients with a history of angioedema related to previous ACE inhibitor therapy.

Directions

Directions for use: Swallow the tablet whole with water, with or without food.

Scientific Evidence

Triplixam combines three antihypertensive agents with complementary mechanisms of action, resulting in enhanced efficacy compared to monotherapy. Perindopril inhibits ACE, amlodipine is a calcium channel blocker, and indapamide is a thiazide-like diuretic. This combination has shown superior blood pressure control in clinical trials.

Studies have demonstrated the effectiveness of perindopril in reducing cardiovascular events in patients with hypertension. Amlodipine has been shown to reduce the risk of stroke and coronary artery disease. Indapamide, in combination with other antihypertensive agents, has shown significant reductions in blood pressure levels.

Additional Information

It is essential to monitor electrolytes and renal function regularly during treatment with Triplixam. Patients should be advised on the signs of hypotension and advised to rise slowly from a sitting or lying position to minimize the risk of dizziness.

Triplixam has a favorable tolerability profile, with most adverse effects being mild and transient. Common side effects include dizziness, headache, and cough. In rare cases, severe allergic reactions may occur, requiring immediate medical attention.